
Chinese General Practice ›› 2024, Vol. 27 ›› Issue (06): 685-691.DOI: 10.12114/j.issn.1007-9572.2022.0765
Special Issue: 高血压最新文章合辑
• Original Research • Previous Articles Next Articles
Received:2022-09-30
Revised:2022-12-26
Published:2024-02-20
Online:2023-11-21
Contact:
LIU Xiaohui
通讯作者:
刘小慧
作者简介:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0765
| 公式名称 | 点尿钠测定样本类型 | 24 h尿钠排泄量估测公式 |
|---|---|---|
| Kawasaki | 清晨空腹第2次尿 | 24 h尿钠排泄量(mmol/d)=16.3×[点尿钠(mmol/L)/点尿肌酐(mg/L)×24 h尿肌酐(mg/d)]0.5 24 h尿肌酐(mg/d)(男)=15.12×体质量(kg)+7.39×身高(cm)-12.63×年龄-79.9 24 h尿肌酐(mg/d)(女)=8.58×体质量(kg)+5.09×身高(cm)-4.72×年龄-74.5 |
| INTERSALT | 随机尿 | 24 h尿钠排泄量(mmol/d)(男)=25.46+0.46×点尿钠(mmol/L)-2.75×点尿肌酐(mmol/L)-0.13×点尿钾(mmol/L)+4.1×BMI+0.26×年龄 24 h尿钠排泄量(mmol/d)(女)=5.07+0.34×点尿钠(mmol/L)-2.16×点尿肌酐(mmol/L)-0.09×点尿钾(mmol/L)+2.39×BMI+2.35×年龄-0.03×年龄2 |
| Tanaka | 随机尿 | 24 h尿钠排泄量(mmol/d)=21.98×[点尿钠(mmol/L)/点尿肌酐(mg/L)×24 h尿肌酐(mg/d)]0.392 24 h尿肌酐(mg/d)=14.89×体质量(kg)+16.14×身高(cm)-2.04×年龄-2 244.45 |
Table 1 Three equations using spot urine samples to estimate 24-hour urinary sodium excretion
| 公式名称 | 点尿钠测定样本类型 | 24 h尿钠排泄量估测公式 |
|---|---|---|
| Kawasaki | 清晨空腹第2次尿 | 24 h尿钠排泄量(mmol/d)=16.3×[点尿钠(mmol/L)/点尿肌酐(mg/L)×24 h尿肌酐(mg/d)]0.5 24 h尿肌酐(mg/d)(男)=15.12×体质量(kg)+7.39×身高(cm)-12.63×年龄-79.9 24 h尿肌酐(mg/d)(女)=8.58×体质量(kg)+5.09×身高(cm)-4.72×年龄-74.5 |
| INTERSALT | 随机尿 | 24 h尿钠排泄量(mmol/d)(男)=25.46+0.46×点尿钠(mmol/L)-2.75×点尿肌酐(mmol/L)-0.13×点尿钾(mmol/L)+4.1×BMI+0.26×年龄 24 h尿钠排泄量(mmol/d)(女)=5.07+0.34×点尿钠(mmol/L)-2.16×点尿肌酐(mmol/L)-0.09×点尿钾(mmol/L)+2.39×BMI+2.35×年龄-0.03×年龄2 |
| Tanaka | 随机尿 | 24 h尿钠排泄量(mmol/d)=21.98×[点尿钠(mmol/L)/点尿肌酐(mg/L)×24 h尿肌酐(mg/d)]0.392 24 h尿肌酐(mg/d)=14.89×体质量(kg)+16.14×身高(cm)-2.04×年龄-2 244.45 |
| 指标 | 女性患者(n=91) | 男性患者(n=105) | χ2(t)值 | P值 |
|---|---|---|---|---|
| 年龄(岁) | 63.0±12.1 | 52.3±14.7 | -5.875a | <0.001 |
| 体质指数(kg/m2) | 26.14±4.15 | 27.49±3.67 | 2.224a | 0.027 |
| 入院收缩压(mmHg) | 151±20 | 148±19 | -0.950a | 0.343 |
| 入院舒张压(mmHg) | 79±15 | 85±16 | 2.776a | 0.006 |
| 24 h平均收缩压(mmHg) | 130±18 | 130±17 | 0.044a | 0.965 |
| 24 h平均舒张压(mmHg) | 71±11 | 78±13 | 4.151a | <0.001 |
| 24 h平均心率(bpm) | 69±10 | 71±9 | 1.181a | 0.239 |
| 夜间血压下降异常[例(%)] | 65(72.2) | 65(63.1) | 1.815 | 0.178 |
| 糖尿病[例(%)] | 26(28.6) | 27(25.7) | 0.202 | 0.653 |
| 高脂血症[例(%)] | 65(71.4) | 69(65.7) | 0.736 | 0.391 |
| 左心室肥厚[例(%)] | 12(13.2) | 12(11.5) | 0.122 | 0.727 |
| 颈动脉内中膜增厚或斑块[例(%)] | 67(75.3) | 75(75.0) | 0.002 | 0.964 |
| 吸烟史[例(%)] | 1(1.1) | 59(56.2) | 69.657 | <0.001 |
| 微量蛋白尿[例(%)] | 28(31.1) | 19(18.1) | 4.488 | 0.034 |
| 临床蛋白尿[例(%)] | 8(8.8) | 2(1.9) | 4.775 | 0.047 |
| 点尿钠(mmol/L) | 101.35±49.49 | 134.44±56.54 | 4.350a | <0.001 |
| 实测24 h尿钠排泄量(mmol/d) | 134.86±62.90 | 193.11±82.00 | 5.458a | <0.001 |
Table 2 Baseline characteristics of enrolled patients with primary hypertension
| 指标 | 女性患者(n=91) | 男性患者(n=105) | χ2(t)值 | P值 |
|---|---|---|---|---|
| 年龄(岁) | 63.0±12.1 | 52.3±14.7 | -5.875a | <0.001 |
| 体质指数(kg/m2) | 26.14±4.15 | 27.49±3.67 | 2.224a | 0.027 |
| 入院收缩压(mmHg) | 151±20 | 148±19 | -0.950a | 0.343 |
| 入院舒张压(mmHg) | 79±15 | 85±16 | 2.776a | 0.006 |
| 24 h平均收缩压(mmHg) | 130±18 | 130±17 | 0.044a | 0.965 |
| 24 h平均舒张压(mmHg) | 71±11 | 78±13 | 4.151a | <0.001 |
| 24 h平均心率(bpm) | 69±10 | 71±9 | 1.181a | 0.239 |
| 夜间血压下降异常[例(%)] | 65(72.2) | 65(63.1) | 1.815 | 0.178 |
| 糖尿病[例(%)] | 26(28.6) | 27(25.7) | 0.202 | 0.653 |
| 高脂血症[例(%)] | 65(71.4) | 69(65.7) | 0.736 | 0.391 |
| 左心室肥厚[例(%)] | 12(13.2) | 12(11.5) | 0.122 | 0.727 |
| 颈动脉内中膜增厚或斑块[例(%)] | 67(75.3) | 75(75.0) | 0.002 | 0.964 |
| 吸烟史[例(%)] | 1(1.1) | 59(56.2) | 69.657 | <0.001 |
| 微量蛋白尿[例(%)] | 28(31.1) | 19(18.1) | 4.488 | 0.034 |
| 临床蛋白尿[例(%)] | 8(8.8) | 2(1.9) | 4.775 | 0.047 |
| 点尿钠(mmol/L) | 101.35±49.49 | 134.44±56.54 | 4.350a | <0.001 |
| 实测24 h尿钠排泄量(mmol/d) | 134.86±62.90 | 193.11±82.00 | 5.458a | <0.001 |
| 患者人群 | 例数 | 24 h尿钠排泄量实测值 | 24 h尿钠排泄量估测值 | t配对值 | P值 |
|---|---|---|---|---|---|
| 女性患者 | 91 | 134.86±62.90 | 194.97±64.55 | -8.786 | <0.001 |
| 男性患者 | 105 | 193.11±82.00 | 237.44±83.30 | -4.274 | <0.001 |
| 糖尿病患者 | 53 | 155.70±75.79 | 219.20±87.73 | -4.850 | <0.001 |
| 非糖尿病患者 | 143 | 168.62±79.77 | 217.03±74.33 | -6.401 | <0.001 |
| 白蛋白尿患者 | 57 | 152.12±73.94 | 235.92±100.39 | -5.926 | <0.001 |
| 无蛋白尿患者 | 139 | 169.15±80.23 | 211.96±69.18 | -5.879 | <0.001 |
| 钠盐摄入量 | |||||
| <6.0 g组 | 40 | 67.18±24.42 | 164.38±67.29 | -9.593 | <0.001 |
| 6.0~8.9 g组 | 51 | 127.33±14.17 | 207.76±75.02 | -7.526 | <0.001 |
| 9.0~11.9 g组 | 58 | 175.86±14.20 | 243.11±76.48 | -6.442 | <0.001 |
| ≥12 g组 | 47 | 276.39±49.53 | 242.73±67.03 | 2.659 | 0.011 |
Table 3 The difference and correlation between the estimated 24-hour urinary sodium excretion by Kawasaki equation and the measured value
| 患者人群 | 例数 | 24 h尿钠排泄量实测值 | 24 h尿钠排泄量估测值 | t配对值 | P值 |
|---|---|---|---|---|---|
| 女性患者 | 91 | 134.86±62.90 | 194.97±64.55 | -8.786 | <0.001 |
| 男性患者 | 105 | 193.11±82.00 | 237.44±83.30 | -4.274 | <0.001 |
| 糖尿病患者 | 53 | 155.70±75.79 | 219.20±87.73 | -4.850 | <0.001 |
| 非糖尿病患者 | 143 | 168.62±79.77 | 217.03±74.33 | -6.401 | <0.001 |
| 白蛋白尿患者 | 57 | 152.12±73.94 | 235.92±100.39 | -5.926 | <0.001 |
| 无蛋白尿患者 | 139 | 169.15±80.23 | 211.96±69.18 | -5.879 | <0.001 |
| 钠盐摄入量 | |||||
| <6.0 g组 | 40 | 67.18±24.42 | 164.38±67.29 | -9.593 | <0.001 |
| 6.0~8.9 g组 | 51 | 127.33±14.17 | 207.76±75.02 | -7.526 | <0.001 |
| 9.0~11.9 g组 | 58 | 175.86±14.20 | 243.11±76.48 | -6.442 | <0.001 |
| ≥12 g组 | 47 | 276.39±49.53 | 242.73±67.03 | 2.659 | 0.011 |
| 患者人群 | rs值 | P值 |
|---|---|---|
| 女性患者 | 0.472 | <0.001 |
| 男性患者 | 0.195 | 0.047 |
| 糖尿病患者 | 0.425 | 0.002 |
| 非糖尿病患者 | 0.386 | <0.001 |
| 白蛋白尿患者 | 0.409 | 0.005 |
| 无蛋白尿患者 | 0.401 | <0.001 |
| 钠盐摄入量 | ||
| <6.0 g组 | 0.319 | 0.045 |
| 6.0~8.9 g组 | -0.016 | 0.913 |
| 9.0~11.9 g组 | 0.014 | 0.915 |
| ≥12 g组 | <0.001 | 0.999 |
Table 4 Correlation analysis between estimated 24-hour sodium excretion by Kawasaki equation and measured 24-hour sodium excretion
| 患者人群 | rs值 | P值 |
|---|---|---|
| 女性患者 | 0.472 | <0.001 |
| 男性患者 | 0.195 | 0.047 |
| 糖尿病患者 | 0.425 | 0.002 |
| 非糖尿病患者 | 0.386 | <0.001 |
| 白蛋白尿患者 | 0.409 | 0.005 |
| 无蛋白尿患者 | 0.401 | <0.001 |
| 钠盐摄入量 | ||
| <6.0 g组 | 0.319 | 0.045 |
| 6.0~8.9 g组 | -0.016 | 0.913 |
| 9.0~11.9 g组 | 0.014 | 0.915 |
| ≥12 g组 | <0.001 | 0.999 |
Figure 1 The consistency of measured 24-hour urine sodium excretion and estimated 24-hour urine sodium excretion by Kawasaki equation evaluated by the Bland-Altman plot
| 患者人群 | 例数 | 24 h尿钠排泄量实测值 | 24 h尿钠排泄量估测值 | t配对值 | P值 |
|---|---|---|---|---|---|
| 女性患者 | 91 | 134.86±62.90 | 107.69±26.42 | 4.678 | <0.001 |
| 男性患者 | 105 | 193.11±82.00 | 174.89±33.58 | 2.008 | 0.047 |
| 糖尿病患者 | 53 | 155.70±75.79 | 139.43±48.83 | 1.651 | 0.105 |
| 非糖尿病患者 | 143 | 168.62±79.77 | 145.26±44.00 | 3.864 | <0.001 |
| 白蛋白尿患者 | 57 | 152.12±73.94 | 140.23±46.24 | 1.179 | 0.244 |
| 无蛋白尿患者 | 139 | 169.15±80.23 | 145.15±45.02 | 4.018 | <0.001 |
| 钠盐摄入量 | |||||
| <6.0 g组 | 40 | 67.18±24.42 | 113.23±40.86 | -6.751 | <0.001 |
| 6.0~8.9 g组 | 51 | 127.33±14.17 | 129.36±43.35 | -0.322 | 0.749 |
| 9.0~11.9 g组 | 58 | 175.86±14.20 | 155.47±43.61 | 3.311 | 0.002 |
| ≥12 g组 | 47 | 276.39±49.53 | 170.61±30.58 | 12.260 | <0.001 |
Table 5 The difference and correlation between the estimated 24-hour urinary sodium excretion by INTERSALT equation and the measured value
| 患者人群 | 例数 | 24 h尿钠排泄量实测值 | 24 h尿钠排泄量估测值 | t配对值 | P值 |
|---|---|---|---|---|---|
| 女性患者 | 91 | 134.86±62.90 | 107.69±26.42 | 4.678 | <0.001 |
| 男性患者 | 105 | 193.11±82.00 | 174.89±33.58 | 2.008 | 0.047 |
| 糖尿病患者 | 53 | 155.70±75.79 | 139.43±48.83 | 1.651 | 0.105 |
| 非糖尿病患者 | 143 | 168.62±79.77 | 145.26±44.00 | 3.864 | <0.001 |
| 白蛋白尿患者 | 57 | 152.12±73.94 | 140.23±46.24 | 1.179 | 0.244 |
| 无蛋白尿患者 | 139 | 169.15±80.23 | 145.15±45.02 | 4.018 | <0.001 |
| 钠盐摄入量 | |||||
| <6.0 g组 | 40 | 67.18±24.42 | 113.23±40.86 | -6.751 | <0.001 |
| 6.0~8.9 g组 | 51 | 127.33±14.17 | 129.36±43.35 | -0.322 | 0.749 |
| 9.0~11.9 g组 | 58 | 175.86±14.20 | 155.47±43.61 | 3.311 | 0.002 |
| ≥12 g组 | 47 | 276.39±49.53 | 170.61±30.58 | 12.260 | <0.001 |
| 患者人群 | rs值 | P值 |
|---|---|---|
| 女性患者 | 0.449 | <0.001 |
| 男性患者 | 0.124 | 0.209 |
| 糖尿病患者 | 0.415 | <0.001 |
| 非糖尿病患者 | 0.472 | <0.001 |
| 白蛋白尿患者 | 0.392 | 0.006 |
| 无蛋白尿患者 | 0.466 | <0.001 |
| 钠盐摄入量 | ||
| <6.0 g组 | 0.085 | 0.600 |
| 6.0~8.9 g组 | 0.006 | 0.965 |
| 9.0~11.9 g组 | -0.012 | 0.931 |
| ≥12 g组 | -0.088 | 0.555 |
Table 6 Correlation analysis between estimated 24-hour sodium excretion by INTERSALT equation and measured 24-hour sodium excretion
| 患者人群 | rs值 | P值 |
|---|---|---|
| 女性患者 | 0.449 | <0.001 |
| 男性患者 | 0.124 | 0.209 |
| 糖尿病患者 | 0.415 | <0.001 |
| 非糖尿病患者 | 0.472 | <0.001 |
| 白蛋白尿患者 | 0.392 | 0.006 |
| 无蛋白尿患者 | 0.466 | <0.001 |
| 钠盐摄入量 | ||
| <6.0 g组 | 0.085 | 0.600 |
| 6.0~8.9 g组 | 0.006 | 0.965 |
| 9.0~11.9 g组 | -0.012 | 0.931 |
| ≥12 g组 | -0.088 | 0.555 |
Figure 2 The consistency of measured 24-hour urine sodium excretion and estimated 24-hour urine sodium excretion by INTERSALT equation evaluated by the Bland-Altman plot
| 患者人群 | 例数 | 24 h尿钠排泄量实测值 | 24 h尿钠排泄量估测值 | t配对值 | P值 |
|---|---|---|---|---|---|
| 女性患者 | 91 | 134.86±62.90 | 161.87±44.05 | -4.524 | <0.001 |
| 男性患者 | 105 | 193.11±82.00 | 173.81±49.54 | 1.992 | 0.049 |
| 糖尿病患者 | 53 | 155.70±75.79 | 170.19±54.05 | -1.336 | 0.187 |
| 非糖尿病患者 | 143 | 168.62±79.77 | 167.51±44.74 | 0.164 | 0.870 |
| 白蛋白尿患者 | 57 | 152.12±73.94 | 181.17±60.37 | -2.696 | 0.010 |
| 无蛋白尿患者 | 139 | 169.15±80.23 | 164.15±42.06 | 0.752 | 0.453 |
| 钠盐摄入量 | |||||
| <6.0 g组 | 40 | 67.18±24.42 | 137.89±44.70 | -10.347 | <0.001 |
| 6.0~8.9 g组 | 51 | 127.33±14.17 | 163.10±46.11 | -5.281 | <0.001 |
| 9.0~11.9 g组 | 58 | 175.86±14.20 | 185.03±44.83 | -1.438 | 0.156 |
| ≥12 g组 | 47 | 276.39±49.53 | 179.30±41.07 | 9.808 | <0.001 |
Table 7 The difference and correlation between the estimated 24-hour urinary sodium excretion by Tanaka equation and the measured value
| 患者人群 | 例数 | 24 h尿钠排泄量实测值 | 24 h尿钠排泄量估测值 | t配对值 | P值 |
|---|---|---|---|---|---|
| 女性患者 | 91 | 134.86±62.90 | 161.87±44.05 | -4.524 | <0.001 |
| 男性患者 | 105 | 193.11±82.00 | 173.81±49.54 | 1.992 | 0.049 |
| 糖尿病患者 | 53 | 155.70±75.79 | 170.19±54.05 | -1.336 | 0.187 |
| 非糖尿病患者 | 143 | 168.62±79.77 | 167.51±44.74 | 0.164 | 0.870 |
| 白蛋白尿患者 | 57 | 152.12±73.94 | 181.17±60.37 | -2.696 | 0.010 |
| 无蛋白尿患者 | 139 | 169.15±80.23 | 164.15±42.06 | 0.752 | 0.453 |
| 钠盐摄入量 | |||||
| <6.0 g组 | 40 | 67.18±24.42 | 137.89±44.70 | -10.347 | <0.001 |
| 6.0~8.9 g组 | 51 | 127.33±14.17 | 163.10±46.11 | -5.281 | <0.001 |
| 9.0~11.9 g组 | 58 | 175.86±14.20 | 185.03±44.83 | -1.438 | 0.156 |
| ≥12 g组 | 47 | 276.39±49.53 | 179.30±41.07 | 9.808 | <0.001 |
| 患者人群 | rs值 | P值 |
|---|---|---|
| 女性患者 | 0.459 | <0.001 |
| 男性患者 | 0.165 | 0.093 |
| 糖尿病患者 | 0.377 | 0.005 |
| 非糖尿病患者 | 0.318 | <0.001 |
| 白蛋白尿患者 | 0.410 | 0.005 |
| 无蛋白尿患者 | 0.331 | <0.001 |
| 钠盐摄入量 | ||
| <6.0 g组 | 0.297 | 0.063 |
| 6.0~8.9 g组 | -0.038 | 0.791 |
| 9.0~11.9 g组 | -0.022 | 0.874 |
| ≥12.0 g组 | -0.060 | 0.691 |
Table 8 Correlation analysis between estimated 24-hour sodium excretion by Tanaka equation and measured 24-hour sodium excretion
| 患者人群 | rs值 | P值 |
|---|---|---|
| 女性患者 | 0.459 | <0.001 |
| 男性患者 | 0.165 | 0.093 |
| 糖尿病患者 | 0.377 | 0.005 |
| 非糖尿病患者 | 0.318 | <0.001 |
| 白蛋白尿患者 | 0.410 | 0.005 |
| 无蛋白尿患者 | 0.331 | <0.001 |
| 钠盐摄入量 | ||
| <6.0 g组 | 0.297 | 0.063 |
| 6.0~8.9 g组 | -0.038 | 0.791 |
| 9.0~11.9 g组 | -0.022 | 0.874 |
| ≥12.0 g组 | -0.060 | 0.691 |
| 钠盐摄入量 | 例数 | K法24 h尿钠排泄量估测值的相对偏差 | I法24 h尿钠排泄量估测值的相对偏差 | T法24 h尿钠排泄量估测值的相对偏差 |
|---|---|---|---|---|
| <6.0 g组 | 40 | -144.69 | -68.54 | -105.25 |
| 6.0~8.9 g组 | 51 | -63.17 | -1.59 | -28.09 |
| 9.0~11.9 g组 | 58 | -38.23 | 11.37 | -5.21 |
| ≥12 g组 | 47 | 12.18 | 38.27 | 35.13 |
Table 9 The relative difference between the estimated 24-hour sodium excretion by three estimation methods and the measured 24-hour sodium excretion
| 钠盐摄入量 | 例数 | K法24 h尿钠排泄量估测值的相对偏差 | I法24 h尿钠排泄量估测值的相对偏差 | T法24 h尿钠排泄量估测值的相对偏差 |
|---|---|---|---|---|
| <6.0 g组 | 40 | -144.69 | -68.54 | -105.25 |
| 6.0~8.9 g组 | 51 | -63.17 | -1.59 | -28.09 |
| 9.0~11.9 g组 | 58 | -38.23 | 11.37 | -5.21 |
| ≥12 g组 | 47 | 12.18 | 38.27 | 35.13 |
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
杜晓甫,陈向宇,张洁,等. 三种点尿法估算中国人群24 h尿钠排泄量的可行性评价[J]. 中华预防医学杂志,2020,54(4):420-424. DOI:10.3760/cma.j.cn112150-20190610-00458.
|
| [14] |
|
| [15] |
|
| [16] |
国家卫生健康委员会. 中国居民营养与慢性病状况报告-2020年[M]. 北京:人民卫生出版社,2021.
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
姜薇,张俊仕,帕提古丽,等. 点尿法及24h尿收集法估算高血压病患者24 h尿钠钾排泄量的应用比较[J]. 中华诊断学电子杂志,2019,7(1):21-25. DOI:10.3877/cma.j.issn.2095-655X.2019.01.005.
|
| [23] |
|
| [24] |
|
| [1] | PAN Ziyun, YIN Hao, LIN Zhirou, MAO Jingyi, HUANG Yan, LUO Yanhua, XIAO Jiafu, HU Yin. From Mechanism to Therapy: Diabetic Autonomic Neuropathy [J]. Chinese General Practice, 2026, 29(21): 2982-2988. |
| [2] | YAN Wen, ZHANG Hanzhi, JIN Hua, QIAN Jie, YU Dehua. Study on the Diagnosis and Treatment Capacity for Depressive Disorders in Community Health Service Institutions in Shanghai [J]. Chinese General Practice, 2026, 29(20): 2790-2799. |
| [3] | CHEN Yiping, ZHANG Jianmei, LI Yanhu, LI Rui, ZHANG Ruiping, YANG Ping. Advances in the Diagnosis and Treatment of Post-COVID-19 Condition of Myocardial Injury [J]. Chinese General Practice, 2026, 29(18): 2585-2592. |
| [4] | AN Xian, HUANG Peng, REN Jingjing. Investigation on the Cognition and Current Status of General Practitioners in the Multidisciplinary Diagnosis and Treatment of Medically Unexplained Symptoms [J]. Chinese General Practice, 2026, 29(18): 2472-2481. |
| [5] | FAN Meixiang, YAN Yunyun, HUANG Yanyan. Interpretation and Discussion of Guidelines for Preventive Activities in General Practice: Bladder Cancer [J]. Chinese General Practice, 2026, 29(18): 2450-2453. |
| [6] | General Practice Branch of Cross-straits Medicine Exchange Association, General Practice Branch of Zhejiang Medical Association, General Undifferentiated Disease Professional Committee of Zhejiang Society of Mathematical Medicine, Chinese Geriatrics Society. Expert Consensus on the Diagnosis, Treatment, and Management of Numbness (2025) [J]. Chinese General Practice, 2026, 29(18): 2433-2449. |
| [7] | LUAN Xiaoqing, SUN Jingjing, LI Xiaoling, WANG Manxia. Research Progress on Potential Biomarkers of Neuromyelitis Optica Spectrum Disorder [J]. Chinese General Practice, 2026, 29(17): 2418-2424. |
| [8] | YAO Dingye, LUO Guiping, SUN Junsheng, LI Hui. Research Progress on Identifying Bipolar Ⅱ Disorder and Depressive Disorder in Primary Care [J]. Chinese General Practice, 2026, 29(15): 2092-2099. |
| [9] | Nephrology Branch of China Association of Chinese Medicine, Nephrology Committee of Guangdong Provincial Association of Chinese Medicine, SU Peiling, YANG Lihong, BAO Kun. Diagnosis and Treatment Guideline of Integrated Traditional Chinese and Western Medicine for Idiopathic Membranous Nephropathy (2025) [J]. Chinese General Practice, 2026, 29(15): 1953-1970. |
| [10] | WANG Siman, ZHANG Mengchu, LI Wen, XU Ai, XU Jin, GUO Rui, YAN Haixia. Research on the Construction of a Risk Prediction Model for Primary Hypertension with Left Ventricular Hypertrophy Based on TCM Syndromes and Pulse Graph Parameters [J]. Chinese General Practice, 2026, 29(14): 1840-1848. |
| [11] | YAN Wenxin, LIU Jue, LIANG Wannian. Perspectives on Key Issues of the General Practice Discipline Development in China [J]. Chinese General Practice, 2026, 29(13): 1649-1653. |
| [12] | ZHANG Hanzhi, JIN Hua, MA Le, SHI Ling, CHEN Chen, HUAN Hongmei, YU Dehua. Analysis of the Quality of Diagnosis and Treatment of Osteoporosis in Shanghai Community Health Service Institutions [J]. Chinese General Practice, 2026, 29(12): 1548-1557. |
| [13] | ZHANG Han, ZHANG Hua, CAI Genshen, LIAN Dongbo, ZHANG Jing. Construction of Weight Loss Clinic in Grassroots Medical Institutions and Typical Case Studies [J]. Chinese General Practice, 2026, 29(12): 1520-1524. |
| [14] | WU Yanyan, DENG Qiancheng, LUO Limin, ZHU Weifang. Clinical Characteristics and Diagnosis and Treatment Analysis of Monkeypox [J]. Chinese General Practice, 2026, 29(11): 1430-1433. |
| [15] | WANG Yuqi, YE Ruixue, GAO Yan, XUE Kaiwen, ZHOU Jing, LI Dongxia, HAO Yingzi, LI Xiaoxuan, WANG Yulong. Rehabilitation Grading Diagnosis System of the Domestic and Foreign Development Present Situation and Application Requirements [J]. Chinese General Practice, 2026, 29(10): 1250-1255. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||